Unfractionated Heparin Reduces the Anti-Platelet Effects of Abciximab but not Eptifibatide During PCI

In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained blood samples at baseline, 10 minutes after standard weight-based abciximab (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated heparin (UFH; 70 U/kg bolus). The median percent inhibition was si...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and applied thrombosis/hemostasis 2006-10, Vol.12 (4), p.458-464
Main Authors: Deliargyris, Efthymios N., Upadhya, Bharathi, Melton, Laura G., Thompson, Cheryl, Fisher, Melrose, Gabriel, Don A., Dehmer, Gregory J., Sane, David C.
Format: Article
Language:English
Subjects:
Adenosine diphosphate
Aged
Angioplasty, Balloon, Coronary
Antibodies, Monoclonal - therapeutic use
Anticoagulants
Anticoagulants - therapeutic use
Blood Coagulation - drug effects
Female
Heparin - therapeutic use
Humans
Immunoglobulin Fab Fragments - therapeutic use
Immunotherapy
Male
Middle Aged
Monoclonal antibodies
Partial Thromboplastin Time
Peptides - therapeutic use
Platelet Aggregation - drug effects
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained blood samples at baseline, 10 minutes after standard weight-based abciximab (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated heparin (UFH; 70 U/kg bolus). The median percent inhibition was significantly higher in the eptifibatide group compared with the abciximab group both before (96.5% [94-100] vs. 85% [77-89.5] [adenosine diphosphate; ADP]; 89.5% [84-95] vs. 59% [37.5-76.5] [thrombin receptor agonist peptide; TRAP], p
ISSN:1076-0296
1938-2723
DOI:10.1177/1076029606293432